Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
about
Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cellsOPN -RevisitedEarly diagnosis of pancreatic cancer: challenges and new developmentsSIBLINGs and SPARC families: their emerging roles in pancreatic cancerTargeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implicationsPancreatic cancer.Serum biomarker panels for the detection of pancreatic cancerReduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.Serum protein markers for early detection of ovarian cancerScreening for pancreatic cancer: why, how, and who?Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.Biology and management of pancreatic cancer.Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancerScreening for pancreatic cancer: current evidence and future directions.Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinomaInduction of osteopontin expression by nicotine and cigarette smoke in the pancreas and pancreatic ductal adenocarcinoma cellsEvaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma PathophysiologyA single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer.Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinomaIdentifying molecular markers for the early detection of pancreatic neoplasia.Toward development of a surface-enhanced Raman scattering (SERS)-based cancer diagnostic immunoassay panel.New tumor-associated antigen SC6 in pancreatic cancer.Osteopontin expression in normal skin and non-melanoma skin tumors.Identifying Biomarkers and Drug Targets Using Systems Biology Approaches for Pancreatic CancerSerum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinomaTarget discovery and validation in pancreatic cancer.Host-derived osteopontin maintains an acute inflammatory response to suppress early progression of extrinsic cancer cells.Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway.Osteopontin and Osteoprotegerin as Potential Biomarkers in Abdominal Aortic Aneurysm before and after TreatmentPancreatic carcinogenesisImproved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.Assessing the statistical significance of the achieved classification error of classifiers constructed using serum peptide profiles, and a prescription for random sampling repeated studies for massive high-throughput genomic and proteomic studies.Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis.RAN GTPase and Osteopontin in Pancreatic Cancer.Molecular pathology of pancreatic cancer: from bench-to-bedside translation.Serum tumor markers in pancreatic cancer-recent discoveries.
P2860
Q24628890-BD2F1B78-963E-4D4B-BDFE-E05BD2832988Q26798763-4D1B2A6A-DCE6-4490-8933-876692D0731AQ27014027-994814B8-B620-4EE8-B127-8289CFDB70EAQ27027759-B24ADED4-5DD0-45B0-99F1-1E844F632876Q28269990-C07DC4AB-70E1-4D14-AA0B-ECD175159A53Q30490247-AB5F54F4-BD39-4234-93A6-E752701DE0D9Q30499531-ABB8FB13-3309-4434-A176-F9C6DF6CAFF8Q33710746-AB435987-0431-4B27-8CCD-C4EDFA3EF88DQ33836343-901FC6C2-6647-46AB-902B-0674F9D37640Q33959412-E5A51090-9326-49B5-8929-1CFBEF96195DQ34275247-8CA62170-DDD5-4242-AA67-CCE8D2D1CE6DQ34482255-A19DFA46-AA25-45A4-85B9-289EF1B35976Q34649019-8050F709-34CA-4505-B3C7-370851E90EFDQ34655823-99B2D850-0290-45FF-9F13-48CC152AEE67Q35014007-886B3B07-73F1-4623-89A7-41505B5E6070Q35152701-05E430AC-F74E-46D4-872A-F47F1E441EDBQ35735234-AFB1B532-173B-4802-8A64-43A9FD7006FDQ35735299-5D77DEA7-228B-42A5-A131-4182BF01F723Q35892368-0F1339CE-6B44-448C-8472-DB70165C88DFQ35903573-0AB3B2F7-9815-4B5A-A1D3-0A89EF81990EQ35911669-17CB9436-70B4-4818-A4BA-8464E6DD382FQ35953813-415066B4-E2B5-4C77-A60D-3B5CE0DDF1C6Q36124027-B4B7F82F-5BF4-4DDE-940C-40C50B03ADD0Q36328508-D5CF5BA2-45A7-4480-8693-777018B33397Q36458892-B8A6DE15-337A-49A8-BA2C-F8AB339F967CQ36503356-0359DDCB-075D-4564-AC70-DE166C6E6710Q36570295-C89DE0E8-D6BF-4D4E-A618-701F6EA2B379Q36573921-FA58EEF6-ECBB-4AF2-BC14-6FB70EDCBBA1Q36622740-CB50B80D-5FA1-452C-A6C7-E9217020DCCCQ36685675-717F27DF-578D-4F36-9C96-6A953CC617CDQ36792616-E00632B3-790F-4C7B-AD8C-025376F45692Q36937276-9E3702C6-29BF-4C45-BB69-45607BC3433EQ36979775-1FE1FD3B-5730-4CD8-BFAE-FB6AF100791AQ37125627-EA58BD85-3D22-4EF6-A73B-A322C8E8594FQ37130537-40008F12-EA1F-4EB1-892E-DD2CE7FC3345Q37133375-424425CA-60AE-4844-B824-DACCD3DE1D69Q37486590-C9F7A6B6-30BA-47E4-A1CC-C056CB98D283Q37707966-592C84F1-0F97-4E94-AC97-84C0F0347E1CQ37998096-92A82D07-4941-4024-AC76-F573D9868047Q38166573-2216177E-C5A8-40E9-BAD2-25ECBB644088
P2860
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
@en
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
@nl
type
label
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
@en
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
@nl
prefLabel
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
@en
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
@nl
P2093
P50
P1476
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma
@en
P2093
Anirban Maitra
Ayman Rahman
Charles J Yeo
Jens Koopmann
Neal S Fedarko
P304
P577
2004-03-01T00:00:00Z